Fenfluramine/Phentermine: The Rise and Fall of Fen-Phen

Fenfluramine/phentermine, widely known as fen-phen, was a combination diet drug that became one of the most prescribed weight-loss treatments in the United States during the mid-1990s before being pulled from the market in 1997 after it was linked to potentially fatal heart valve damage and pulmonary hypertension. The episode remains one of the most significant drug safety disasters in modern history, reshaping how obesity medications are developed, tested, and monitored. Yet both drugs in the combination have continued to play roles in medicine, sometimes in unexpected ways.

Why Two Drugs Were Combined in the First Place

Fenfluramine and phentermine affect the brain through different chemical pathways. Fenfluramine works primarily on serotonin, releasing it from nerve terminals and blocking its reuptake, which suppresses appetite through serotonin-driven satiety signals.¹ Phentermine, on the other hand, is a stimulant that acts on norepinephrine and, to a lesser extent, dopamine. On its own, phentermine produces effects resembling those of amphetamine, while fenfluramine tends to cause drowsiness, anxiety, and confusion. When given together, phentermine blunted the unpleasant effects of fenfluramine, and the combination appeared to have low abuse potential.²

The logic was appealingly simple: use lower doses of each drug so that neither one’s side effects dominated, while their appetite-suppressing effects stacked. A 1984 clinical trial tested this idea head-on. People taking the combination lost about 8.4 kg on average, compared to 4.4 kg for those on placebo, and side effects were less frequent than with either drug alone at full dose.³ The combination looked, at first, like a genuine advance.

The Clinical Results That Fueled the Craze

The study that truly launched fen-phen into mainstream medicine was published in 1992 by Michael Weintraub and colleagues. In that trial, participants taking fenfluramine plus phentermine alongside a program of behavior modification, calorie restriction, and exercise lost an average of about 14 kg, or roughly 16% of their starting body weight, over 34 weeks. Those on placebo with the same lifestyle program lost about 4.6 kg.⁴ These results were striking for the era, and the study’s multi-year design gave it an air of long-term credibility that shorter diet drug trials lacked.

Media coverage amplified the findings. Doctors began prescribing the two drugs in combination off-label (neither the FDA nor the manufacturer had formally approved the specific pairing), and demand exploded. By 1996, an estimated 18 million prescriptions for fenfluramine or dexfenfluramine (a chemically related variant) were being written in the U.S. annually. Strip-mall diet clinics sprang up offering fen-phen with minimal medical supervision, and the drug became a cultural phenomenon.

How Heart Valve Damage Was Discovered

The crisis broke in the summer of 1997. A group of physicians at the Mayo Clinic identified 24 women, all taking fen-phen and none with a prior history of heart disease, who had developed unusual valve abnormalities. On echocardiography, every one of them showed abnormal valve structure and leaking (regurgitation) on both the left and right sides of the heart. Eight also had newly documented pulmonary hypertension. Five required cardiac surgery.⁵

What the surgeons saw during those operations was distinctive and unsettling. The valves had a glistening white appearance, with plaque-like deposits encasing the leaflets and the chord-like structures that anchor them. The underlying valve architecture remained intact beneath these plaques, which resembled the kind of valve damage seen in carcinoid tumors or in people exposed to ergot-derived drugs. This was not garden-variety valve disease from aging or infection; it was something pharmacologically specific.

On July 8, 1997, the FDA issued a public health advisory and sent letters to roughly 700,000 healthcare practitioners and institutions requesting reports of similar cases. Reports flooded in. By September, the FDA had asked the manufacturers to voluntarily withdraw fenfluramine and dexfenfluramine from the market, and they complied.⁶ Phentermine, which had not been linked to valve damage on its own, stayed on the market.

What Was Actually Happening to the Heart Valves

Subsequent pathology studies painted a detailed picture of the damage. Explanted valves from affected patients showed irregular thickening of the leaflets and fusion of the chords in the mitral valves. Under a microscope, the characteristic finding was fibromyxoid plaques and nodules just beneath the valve surface, sitting on top of a generally intact elastic fiber layer. Immune cells were present in the tissue, along with central degenerative changes that ranged from mild to marked depending on the patient.⁷ Some studies estimated the prevalence of clinically meaningful valve disease among users at as high as 23%, though the true rate depended heavily on how long people took the drugs and what criteria were used to define disease.⁸

The molecular culprit turned out to be a specific serotonin receptor called 5-HT2B. Fenfluramine is metabolized in the body to norfenfluramine, which is a potent activator of this receptor. Heart valve tissue has 5-HT2B receptors on its surface, and when these receptors are chronically stimulated, the result is the kind of fibrotic overgrowth that pathologists were seeing on the explanted valves.⁹ This finding, connecting a specific receptor to the valve damage, was a breakthrough in understanding not just fen-phen but the broader category of serotonin-related valve disease that had been observed with carcinoid tumors and certain migraine drugs.¹⁰

Pulmonary Hypertension as a Parallel Threat

Valve damage was not the only cardiovascular danger. Fenfluramine was also linked to pulmonary arterial hypertension (PAH), a condition in which blood pressure in the arteries of the lungs rises abnormally, eventually straining and damaging the right side of the heart. A study of 109 patients who developed PAH after fenfluramine exposure found that the median duration of drug use was about six months, with a median gap of four and a half years between stopping the drug and the onset of symptoms. That delay is worth emphasizing: people could develop life-threatening lung disease years after their last pill. The clinical and survival profiles of these patients were essentially identical to those with the spontaneous, idiopathic form of PAH, suggesting that fenfluramine acted as a powerful trigger but did not alter the disease’s course once it took hold.¹¹

Some patients had both conditions simultaneously. An autopsy case of a 36-year-old woman who had taken fen-phen for seven months revealed combined cardiac valve disease and pulmonary hypertension, illustrating how the two pathologies could coexist and compound each other’s lethality.¹² This combination was not a freak occurrence; clinicians at the time believed it happened frequently enough that further autopsy studies were needed to understand just how common it was.

The Legal and Financial Fallout

The fen-phen disaster produced one of the largest pharmaceutical settlements in history. American Home Products (later Wyeth), the maker of fenfluramine and dexfenfluramine, agreed to a $3.75 billion settlement in 1999 to resolve hundreds of thousands of lawsuits filed by patients who developed valve damage.¹³ The settlement funded both direct compensation for people with documented valve disease and medical monitoring for anyone who had taken the drug combination. In practice, the costs ballooned beyond even that staggering figure as additional claims were processed over the following decade. Some legal analysts estimate the total payout ultimately exceeded $13 billion when later settlements and trust fund disbursements are included, though numbers vary depending on the accounting.

The litigation also exposed how aggressively the drugs had been marketed and how loosely they were prescribed. Documents revealed that warnings about potential heart effects had circulated internally well before 1997. For many people who followed the fen-phen saga, the case became a cautionary tale not just about drug safety but about the gap between pharmaceutical marketing and patient welfare.

Phentermine Stayed on the Market

One of the less-discussed aspects of the fen-phen story is that phentermine itself was never withdrawn. The evidence consistently pointed to fenfluramine and its metabolites as the cause of valve damage, not phentermine. After the withdrawal, phentermine continued to be prescribed as a short-term appetite suppressant, and it remains available today. A large observational study using electronic health records found that patients who used phentermine alone for longer than three months lost more weight without an increased risk of cardiovascular disease or death compared to non-users.¹⁴

Phentermine also found a second act in a new combination. In 2012, the FDA approved a controlled-release formulation pairing phentermine with topiramate, an antiseizure medication. The CONQUER trial, a large phase 3 study, showed that the higher-dose combination produced about 10 kg of weight loss at 56 weeks, with roughly 70% of participants losing at least 5% of their body weight, compared to 21% on placebo.¹⁵ A more recent trial in Korean adults confirmed similar results, with about 8% weight loss over 56 weeks.¹⁶ Topiramate does not activate 5-HT2B receptors, so the valvulopathy concern that doomed the fenfluramine pairing does not apply here.

Fenfluramine’s Unexpected Second Life in Epilepsy

Perhaps the most surprising chapter in the fen-phen story involves fenfluramine alone. After its withdrawal for weight loss, researchers noticed that children with Dravet syndrome, a severe form of epilepsy that resists most standard medications, sometimes experienced dramatic reductions in seizures when given low-dose fenfluramine. This observation traced back to anecdotal reports from Belgium in the 1980s and 1990s, and it was eventually tested in rigorous trials.

A randomized trial published in The Lancet found that low-dose fenfluramine significantly reduced convulsive seizures in children with Dravet syndrome compared to placebo, and cardiac monitoring showed no valvular heart disease or pulmonary arterial hypertension at the doses used.¹⁷ Another trial found that patients on fenfluramine achieved about a 54% greater reduction in seizure frequency than those on placebo, with more than half the fenfluramine group experiencing a 50% or greater drop in seizures compared to just 5% in the placebo group.¹⁸

The key difference from the fen-phen era is dose. The appetite-suppressing doses of fenfluramine that caused heart problems were far higher than the doses used for seizure control. Reviews of the clinical trial data have confirmed that the valvulopathy concerns have not materialized with low-dose fenfluramine for epilepsy.¹⁹ Fenfluramine was approved in 2020 by the FDA for Dravet syndrome under a risk evaluation and mitigation strategy (REMS) program, which requires regular cardiac monitoring with echocardiograms. It has since been expanded to cover Lennox-Gastaut syndrome as well. For families dealing with these devastating epilepsy syndromes, a drug that was once synonymous with medical scandal now represents genuine hope.

How Fen-Phen Reshaped Obesity Drug Regulation

The fen-phen disaster did not just remove two drugs from the market; it fundamentally changed the rules of the game for obesity pharmacotherapy. Before 1997, diet pills were approved with relatively modest safety data, and off-label combinations were common. After fen-phen, and after subsequent withdrawals of other weight-loss drugs for their own safety problems (including sibutramine for cardiovascular events and rimonabant for psychiatric side effects in Europe), the FDA adopted a much more cautious posture.²⁰

New regulatory strategies that emerged directly from this history include mandatory risk evaluation and mitigation programs, requirements for large cardiovascular outcome trials either before or after approval, built-in “responder” criteria that limit continued use to people who actually lose weight within a set timeframe, and post-marketing safety surveillance. Every obesity drug approved since the fen-phen era has been shaped by these requirements.

The 5-HT2B receptor story also had direct consequences for drug design. When lorcaserin, a newer serotonin-based weight-loss drug, was developed, its designers deliberately engineered it to be highly selective for the 5-HT2C receptor over 5-HT2B, with roughly 100-fold selectivity between the two.²¹ Clinical trials included echocardiographic monitoring to specifically check for valve changes, a precaution that would not have existed without the fen-phen precedent.²² Lorcaserin was ultimately withdrawn for a different reason (a cancer signal in long-term data), but its development illustrated how deeply the 5-HT2B lesson had been absorbed by the field.

What Fen-Phen Did and Did Not Prove About Diet Pills

A common misconception that persists from the fen-phen era is that all diet pills are inherently dangerous, or that the drugs “never really worked.” Neither is accurate. Fen-phen genuinely produced meaningful weight loss in clinical trials. The problem was not efficacy but a specific, serious toxicity that went undetected until millions of people had already been exposed. The broader lesson is about the limits of short-term safety data when a drug is given to a large, otherwise healthy population for months or years.

Another persistent misunderstanding involves phentermine. Many people assume phentermine was part of the heart damage story and avoid it out of fear. In reality, the pharmacological evidence consistently points to fenfluramine’s metabolite norfenfluramine, acting on 5-HT2B receptors, as the cause.²³ Phentermine works on norepinephrine, not serotonin, and has its own separate safety profile (mostly related to stimulant effects like elevated heart rate and blood pressure) that has nothing to do with valve fibrosis.

The fen-phen episode also left a lasting cultural mark on how physicians and patients think about weight-loss medication. For years after 1997, many doctors were reluctant to prescribe any obesity drugs, and patients were reluctant to take them. That hesitancy has only recently begun to shift with the arrival of GLP-1 receptor agonists like semaglutide, which work through an entirely different mechanism and were tested in the large cardiovascular outcome trials that the fen-phen era made mandatory. Whether the new generation of drugs will have its own long-term surprises remains to be seen, but the regulatory infrastructure designed to catch those surprises exists in large part because of what happened with fen-phen.